AI and the Future of Biomarkers in Prostate Cancer

"The landscape of prostate cancer management has evolved significantly over the past 30 years, with [active surveillance], advances in imaging and genetics, and improvements in the treatment of high-risk disease marking key areas of progress," writes Michael S. Cookson, MD, MMHC.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

“Our findings give patients and doctors valuable insights into what to expect after ADT treatment, helping them make informed decisions about managing side effects and improving long-term outcomes," says Amar U. Kishan, MD.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP.

Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.